Q32 Bio (QTTB) Interest Expenses (2017 - 2026)
Q32 Bio (QTTB) posted quarterly Interest Expenses of $8.4 million for Q1 2026, up 644.22% year-over-year from $1.1 million in Q1 2025, and up 4082.5% quarter-over-quarter from $200000.0 in Q4 2025.
Q32 Bio (QTTB) Interest Expenses (2017 - 2026) Analysis & Trends
Q32 Bio's Interest Expenses history runs 10 years deep, the most recent figure standing at $8.4 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 644.22% year-over-year to $8.4 million; the TTM figure through Mar 2026 stood at $8.4 million (up 644.22% YoY), while the FY2025 annual figure was $7.1 million, down 93.39% from the prior year.
- Interest Expenses for Q1 2026 stood at $8.4 million, up from $200000.0 in the prior quarter.
- The five-year high for Interest Expenses was $179.7 million in Q4 2022, with the low at $200000.0 in Q4 2025.
- The 5-year median for Interest Expenses is $7.6 million (2025), against an average of $25.2 million.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses sank 99.46% in 2023, then jumped 12774.59% in 2024.
- Q32 Bio's Interest Expenses stood at $179.7 million in 2022, then tumbled by 97.77% to $4.0 million in 2023, then sank by 90.0% to $400000.0 in 2024, then slumped by 50.0% to $200000.0 in 2025, then surged by 4082.5% to $8.4 million in 2026.
- Business Quant data shows QTTB's Interest Expenses at $8.4 million in Q1 2026, $200000.0 in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Q32 Bio | 359.61 Mn | 253.31 Mn | - | 21.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.61 Mn |
| Jun 30, 2026 | 21.61 Mn |
| Mar 31, 2026 | 8.37 Mn |
| Mar 31, 2026 | 8.37 Mn |
| Dec 31, 2025 | 200,000.00 |
| Dec 31, 2025 | 200,000.00 |
| Sep 30, 2025 | 1.12 Mn |
| Sep 30, 2025 | 1.12 Mn |
| Jun 30, 2025 | 7.59 Mn |
| Jun 30, 2025 | 7.59 Mn |
| Mar 31, 2025 | 1.12 Mn |
| Mar 31, 2025 | 1.12 Mn |
| Dec 31, 2024 | 400,000.00 |
| Dec 31, 2024 | 400,000.00 |
| Sep 30, 2024 | 62.83 Mn |
| Sep 30, 2024 | 62.83 Mn |
| Jun 30, 2024 | 12.00 Mn |
| Jun 30, 2024 | 12.00 Mn |
| Mar 31, 2024 | 10.62 Mn |
| Mar 31, 2024 | 10.62 Mn |